OUR MENTORS Our prestigious leaders have expertise in almost all business sectors and situations.

 Ewan Kirk

Ewan Kirk

Experienced Chair: Private

Experienced Founder and Chief Investment Officer 

  • Over 30 years of international senior leadership experience
  • Multi-industry knowledge in deep technology, financial services, quantitative investment management, fundamental mathematics, defence, security and infosec, clean-tech, education, private equity, venture capital
Download Mentor Bio PDF Share Mentor Bio Print Mentor Bio

Major Career Roles

Ewan Kirk is a technology entrepreneur, early-stage investor, and founder of Cantab Capital Partners. He is a non-executive director of defence company BAE Systems plc, and sits on the Board of a number of UK technology start-ups. He is Chairman of DeepTech Labs, a Cambridge-based accelerator that identifies, invests in and scales startups that commercialise frontier scientific technology. He is also Chair of the Management Committee at the Isaac Newton Institute for Mathematical Sciences at the University of Cambridge.


Ewan is the Co-founder and Co-chair of the Turner Kirk Trust, an evidence-led, strategic charitable foundation, which supports STEM, education and conservation causes in the UK and the developing world. The Trust is one of the largest private funders of fundamental mathematics research in the UK.

Industry Knowledge

Ewan Kirk has over 30 years of experience identifying and commercialising research opportunities in mathematics, technology, and physics, especially across data science, machine learning (ML), and artificial intelligence (AI). He has a special expertise in establishing 'horizon scanning' functions to identify key areas of emerging science that provide commercial opportunities and risks to the organisations he has led and invested in.

Ewan founded Cantab Capital Partners in 2006, a science-led quantitative investment management firm, one of the first hedge funds to apply cutting-edge data science research to the financial markets to develop algorithm-led strategies. After the acquisition of the business in 2016 by GAM Investments, he went on to serve as the president of GAM Systematic Cantab until March 2021. He was previously Partner and Head of Quantitative Technology at Goldman Sachs, where he helped establish the bank's European quant operations through the recruitment of more than 120 scientists, mathematicians, and technologists. He created an exploratory scientific research culture at the bank to appeal to the most competitive STEM talent.

 

Mentor suggestions

Sir John Parker

Sir John Parker

Sir John Parker has been Chairman of Pennon Group plc and South West Water Ltd, Chairman of National Grid plc, Anglo American plc, Mondi, BVT Joint Venture, RMC Group plc and P&O plc. He has served as Chairman and CEO of both Harland & Wolff and Babcock International. He is currently the Chairman of construction and engineering company Laing O'Rourke.

FULL BIO

 Glen Moreno

Glen Moreno

Glen Moreno is Non-Executive Director of Fidelity International Ltd, one of the world’s leading investment companies. He was previously Chairman of Pearson plc, a global publishing and educational business, Chairman of Virgin Money plc and served as Acting Chairman of UK Financial Investments, the organisation created to manage the UK government’s investment in troubled banks.

FULL BIO

 Eldar Sætre

Eldar Sætre

Eldar Sætre recently stepped down as CEO of Equinor ASA, the largest oil and gas group on the Norwegian continental shelf and a major global energy company with presence in more than 30 countries. Eldar is a member of the Board of Subsea 7 SA, Fjord Base Holding AS and Trucknor AS and he is Chairman of the Board of Strømberg Gruppen AS, Vartdal Holding AS and Vartdal Plastindustri AS.

FULL BIO

Dr Franz Humer

Dr Franz Humer

Dr Franz Humer was previously Chairman of Roche Holding AG and is Chairman of Neogene Therapeutics and HMNC Brain Health. He is a Board Director of Allogene Therapeutics, Cydar and Emil Frey Holdings and an Advisor to Temasek Holdings, Letterone Healthcare, Target PharmaSolutions and Breakthrough Properties in addition to a number of start-up companies.

FULL BIO